Wednesday, June 10, 2026
🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
2,004

Quick answer

2,004 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 11649438

    Methods and compositions for treating cancer

    CRISPR THERAPEUTICS AG · Granted Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11648307

    Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy

    The Board of Regents of the University of Texas System · Granted Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11642401

    Activation of resident memory T cells for cancer immunotherapy

    Regents of the University of Minnesota · Granted Tue May 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11642354

    Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer

    The Board of Regents of the University of Texas System · Granted Tue May 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11643656

    Antisense therapies for treating cancer

    The United States Government represented by the Department of Veterans Affairs · Granted Tue May 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11642331

    Glucocorticoid receptor modulators to treat pancreatic cancer

    Corcept Therapeutics Incorporated · Granted Tue May 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11640848

    Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden

    REGENERON PHARMACEUTICALS, INC. · Granted Tue May 02 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11638704

    Bicyclic compounds and their use in the treatment of cancer

    TEMPEST THERAPEUTICS, INC. · Granted Tue May 02 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11633385

    Combination compositions for treatment of cancer

    RedHill Biopharma Ltd. · Granted Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11634482

    Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer

    Julius-Maximilians-Universitat Wurzburg · Granted Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11629334

    Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood

    THE UNITED STATES OF AMERICA, represented by the Secretary, Department of Health and Human Services · Granted Tue Apr 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11622977

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Tue Apr 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11618888

    Tumor-selective E1A and E1B mutants

    The Regents of the University of California · Granted Tue Apr 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11613754

    Toxic RNAi active seed sequences for killing cancer cells

    Northwestern University · Granted Tue Mar 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11607464

    Compositions and methods for the treatment and imaging of cancer

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Mar 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11607426

    Method of targeting oncolytic viruses to tumors

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Mar 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11607450

    Smallpox vaccine for cancer treatment

    Calidi Biotherapeutics, Inc. · Granted Tue Mar 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11603412

    Antibodies against CDCP1 for the treatment and detection of cancer

    The Regents of the University of California · Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11603376

    Compositions and methods for treating cancer

    The Regents of the University of California · Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11596633

    SHP2 inhibitor compositions and methods for treating cancer

    Revolution Medicines, Inc. · Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11596660

    Methods of treating bladder cancer

    CG ONCOLOGY, INC. · Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11591579

    Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy

    The Board of Regents of the University of Texas System · Granted Tue Feb 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11583526

    Treatment of prostate cancer

    Takeda Pharmaceutical Company Limited · Granted Tue Feb 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11578371

    Biomarkers for predicting tumor response to and toxicity of immunotherapy

    MIRA DX, INC. · Granted Tue Feb 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11571446

    Gut microbiota and treatment of cancer

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11572408

    Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent

    VACCINEX, INC. · Granted Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11572541

    Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer

    Providence Health & Services—Oregon · Granted Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11572413

    Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

    PRECISION BIOLOGICS, INC. · Granted Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11571484

    Compositions that target tumor-associated macrophages and methods of use therefor

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11566076

    Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers

    Five Prime Therapeutics, Inc. · Granted Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11564954

    Tumor-delivered multi-target therapeutics for colon cancer

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11560356

    Compounds and compositions for the treatment of cancer

    The Regents of the University of California · Granted Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11559583

    Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer

    Five Prime Therapeutics, Inc. · Granted Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11559574

    Whole-cell cancer vaccines and methods for selection thereof

    BriaCell Therapeutics Corp. · Granted Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11560414

    Kits comprising myokines and platinum-based chemotherapeutic agents for treating colorectal cancer

    Northwestern University · Granted Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11554140

    Nucleic acid, chimeric antigen receptor expression plasmid, chimeric antigen receptor expressing cell, use thereof, and pharmaceutical composition for treating cancer

    China Medical University Hospital · Granted Tue Jan 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11555057

    Compositions and methods for inhibiting tumor cells by inhibiting the transcription factor ATF5

    The Regents of the University of California · Granted Tue Jan 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11555056

    Methods and materials for treating cancer

    Mayo Foundation for Medical Education and Research and Board of Regents · Granted Tue Jan 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11541077

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11541045

    Methods of treating cancer with farnesyltransferase inhibitors

    Kura Oncology, Inc. · Granted Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11529372

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11529363

    Methods of treating cancer in pediatric patients

    Takeda Pharmaceutical Company Limited · Granted Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11524017

    Method of using substrates of AKR1B1/AKR1B10 as anti-cancer drugs

    Beijing Normal University Hong Kong Baptist University United International College · Granted Tue Dec 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11524044

    Strengthening and tumor eliminating traditional Chinese medicine composition, its preparation method and application

    The First Afiliated Hospital of Guangzhou University of Chinese Medicine · Granted Tue Dec 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11517592

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Dec 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11519007

    Tumor-navigating, self-eradicating, trail-armed salmonella for precision cancer therapy

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Dec 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11512141

    Fibrinogen-like protein 2 (FGL2) monoclonal antibodies and their use in cancer detection and treatment

    The Board of Regents of the University of Texas System · Granted Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. CA 3217490

    MASITINIB POUR LE TRAITEMENT DU CANCER DE LA PROSTATE RESISTANT A LA CASTRATION

    AB SCIENCE [FR] · Granted Thu Nov 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Nov 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

2,004 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.